Clinical Trial Update: TaxXel: Taxotere and Xeloda in Esophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

An early-phase study (Phase 1/2) evaluating the combination of Taxotere (docetaxel) and Xeloda (capecitabine) in esophageal cancer and gastric cardia cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cardia Cancer

Drugs mentioned

• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Karolinska University Hospital | Conditions: Cancer of the Esophagus, Gastric Cardia Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN